Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label phase 2 study of topical terbinafine hydrochloride 2.4% for mild to moderate onychomycosis
MOH_2022-02-15_010581Phase 2Not yet recruiting
- Sponsor
- LDS
- Start
- Feb 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of AP4500 in onychomycosis, sponsored by LDS. Planned start Feb 2022; status: not yet recruiting.
02
Drugs
AP4500
03
Conditions
onychomycosis
Beyond the preview
Go deeper on MOH_2022-02-15_010581.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2022-02-15_010581.